Skip to main content

ICD-10-PCS FY2027 code changes

Current release · ICD-10-PCS FY2027 · Effective October 1, 2026

Part of FY2027 coding changes

Every recorded ICD-10-PCS code addition, deletion, description revision, billable-status change and tabular-instruction change for FY2027, effective October 1, 2026.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

Release
ICD-10-PCS FY2027
Effective
October 1, 2026
Code set period
2026-10-01 onward
Source data last read
September 13, 2026
Source file
icd10pcs_codes_2027.txt

This release adds 101 ICD-10-PCS codes, deletes 38, and revises 3 titles, measured against the April 2026 mid-year set. New Technology Group 12 arrives with 52 codes, Group 7 expires on schedule, and two Group 7 technologies graduate into the standard tables with direct successors. Effective October 1, 2026.

FY2027 at a glance

101Added101 of them valid for submission38Deleted38 were valid for submission3Revised descriptionsSame code, different wording

Explore the complete recorded change list →

What matters for coders

A code-set update reaches day-to-day coding in more than one place. The themes below are this release's highest-impact changes; each one can affect any of these:

  • Code selection. A new subcategory can move the correct code for a diagnosis a coder has reported the same way for years.
  • Specificity. Where a parent gains children, the documentation has to support the more specific choice.
  • Billable status. A code that remains in the tabular is not necessarily valid for submission; a parent that gains children stops being reportable on its own.
  • Sequencing. Code first, Code also and Use additional code instructions change which code leads and which must accompany it.
  • Replacement codes. A deleted code needs a determined successor, or an explicit statement that none was published.
  • Documentation requirements. Laterality, trimester, encounter and severity children only pay off when the note records them.
  • Code-family navigation. Excludes1 and Excludes2 edits redraw which codes may be reported together.

New Technology Group 12 (52 codes)

The annual X-section cohort: a leadless vagus-nerve neurostimulator, small-diameter tibial and peroneal artery stents, transcatheter septal scoring, three new transcatheter valve devices, branched thoracic-aorta devices, single-use cholangioscopes and choledochoscopes, carbon/PEEK spinal stabilization at four cervical-thoracic levels, a contractility-modulation-plus-defibrillator generator, and a large batch of computer-aided detection, triage, and intraprocedural-guidance codes spanning CT, echocardiography, ECG, vital signs, and cardiac conduction mapping.

  • X0HQ05C — Insertion of Leadless Neurostimulator Generator into Vagus Nerve, Open Approach, New Technology Group 12
  • X28M3DC — Division of Ventricular Septum using Transcatheter Septal Scoring Technique, Percutaneous Approach, New Technology Group 12
  • XEZZXMC — Computer-Aided Detection and Notification for Abnormalities in Electrocardiogram, New Technology Group 12
  • XRH10NC — Insertion of Carbon/PEEK Spinal Stabilization Device into Cervical Vertebral Joint, Open Approach, New Technology Group 12
  • XW0337C — Introduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12

Standard-table additions (49 codes in sections 0, 3, 5 and B)

Beyond the X section: native- and prosthetic-leaflet qualifiers for percutaneous aortic and mitral valve division, an active-mechanical-clearance drainage device value for pleural cavities and mediastinum, high-dose immune globulin as a named transfusion substance, selective-cytopheresis urinary filtration at all three duration tiers, an impeller-pump circulatory-decompression assistance code, and fluorescing-agent imaging of the choroid and retinal vessels.

  • 028F3Z0 — Division of Aortic Valve, Percutaneous Approach, Native Leaflet
  • 0W99303 — Drainage of Right Pleural Cavity with Drainage Device, Active Mechanical Clearance, Percutaneous Approach
  • 30233S5 — Transfusion of High-Dose Immune Globulin into Peripheral Vein, Percutaneous Approach
  • 5A1D901 — Performance of Urinary Filtration, Continuous, Greater than 18 hours Per Day, Selective Cytopheresis
  • B85G2ZZ — Other Imaging of Right Retinal Vessel using Fluorescing Agent

New Technology Group 7 expires (38 deletions)

The scheduled sunset of the FY2021-vintage cohort: drug and biologic introduction codes (terlipressin, trilaciclib, lurbinectedin, amivantamab, fostamatinib, anacaulase, tixagevimab and cilgavimab), high-dose IVIG transfusion, radial-artery thermal-resistance bypass, GI oxygen-saturation monitoring, custom-made interbody fusion, and two measurement codes. Two of these technologies continue under new standard-table codes — see the successor rows below; the rest expire without a dedicated replacement.

  • XW03367 — Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • X2KB317 — Bypass Right Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7

Compare a code

Enter any ICD-10-PCS code to see what this release does to it: added, deleted, description revised, billable status changed, new child codes, or no change at all. The answer is a lookup against the recorded changes below — nothing is generated.

Deleted codes — what to report instead

These codes leave the code set on October 1, 2026. Where a successor was determined from the source files it is named below; where none was, that is stated rather than guessed.

No successor was determined for these codes.

No direct successors are added. Per the New Technology section’s design, expired X codes stop being reportable and the underlying procedures fall back to the standard tables’ existing root-operation codes; the specific technology is no longer separately identifiable.

FY2026 (April) codeFY2026 (April) descriptionFY2027 statusEffective
X2KB317Bypass Right Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026

No successor was determined for these codes.

FY2026 (April) codeFY2026 (April) descriptionFY2027 statusEffective
X2KC317Bypass Left Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XD2G4V7Monitoring of Upper GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XD2G8V7Monitoring of Upper GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XD2H4V7Monitoring of Lower GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XD2H8V7Monitoring of Lower GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGA0R7Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGA3R7Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGA4R7Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGB0R7Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGB3R7Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGB4R7Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGC0R7Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGC3R7Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGC4R7Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGD0R7Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGD3R7Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XRGD4R7Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW01397Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW01X27Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW023X7Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW03367Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW03377Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW03387Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW033B7Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW04367Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW04377Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW04387Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW043B7Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW0DXR7Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW0G7R7Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW0H7R7Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XW133F8Transfusion of OTL-103 into Peripheral Vein, Percutaneous Approach, New Technology Group 8Deleted — not valid for submissionOctober 1, 2026
XW143D7Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XXE5XR7Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026
XXE5XT7Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026

No successor was determined for these codes.

No named successor. The FY2027 set does add “Other Enzymatic/Chemical Agent” introduction codes at the same two body sites and approach (3E00XGF, 3E01XGF), which is the plausible landing place — confirm against the official mapping before treating it as a crosswalk.

FY2026 (April) codeFY2026 (April) descriptionFY2027 statusEffective
XW00X27Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026

Report instead: 30233S5, 30243S5

A graduation into the section 3 transfusion table: high-dose immune globulin becomes a named substance value for peripheral and central vein, same approach.

FY2026 (April) codeFY2026 (April) descriptionFY2027 statusEffective
XW133D7Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7Deleted — not valid for submissionOctober 1, 2026

FY2027 codes in 30233S5, 30243S5

  • 30233S5 — Transfusion of High-Dose Immune Globulin into Peripheral Vein, Percutaneous Approach

Listed from the release's own code descriptions. Choose by documentation; this is not a published one-to-one crosswalk.

Revised descriptions

The code itself is unchanged; its description is not. A reworded title can move which diagnoses belong under it.

XW0E33B

Introduction of DB-OTO via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11

→ Introduction of Lunsotogene Parvec-cwha via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11

The development-name gene therapy takes its nonproprietary name; the code itself is unchanged.

XW0V0P7

Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7

→ Introduction of Gentamicin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7

Narrowed from any antibiotic to gentamicin specifically — relevant because a vancomycin-eluting filler now has its own Group 12 code (XW0V0BC).

XW143F8

Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8

→ Transfusion of Etuvetidigene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8

Development name replaced by the nonproprietary name; coders searching by either should land on the same code.

All three are renames of the same code, not new codes — mappings and encoder favorites keyed to the old drug names still resolve to the same seven characters.

When do ICD-10-PCS FY2027 codes take effect?

ICD-10-PCS is reported on inpatient claims, where the discharge date governs: these codes apply to discharges on or after October 1, 2026, including stays that began in September. The baseline for this comparison is the April 2026 mid-year update, so codes added mid-year are not re-counted here.

The full recorded change list

Every recorded change, grouped by what kind of change it is. Each entry shows the code's own description first; tabular instructions and relationship text are labeled separately beneath it.

Added to the code set (101)

  • 028F3Z0 — Division of Aortic Valve, Percutaneous Approach, Native Leaflet
  • 028F3Z1 — Division of Aortic Valve, Percutaneous Approach, Prosthetic Leaflet
  • 028G3Z0 — Division of Mitral Valve, Percutaneous Approach, Native Leaflet
  • 028G3Z1 — Division of Mitral Valve, Percutaneous Approach, Prosthetic Leaflet
  • 0RGA0E0 — Fusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Open Approach
  • 0RGA0EJ — Fusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Open Approach
  • 0RGA3E0 — Fusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Approach
  • 0RGA3EJ — Fusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Approach
  • 0RGA4E0 — Fusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0RGA4EJ — Fusion of Thoracolumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG00E0 — Fusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Open Approach
  • 0SG00EJ — Fusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Open Approach
  • 0SG03E0 — Fusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Approach
  • 0SG03EJ — Fusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Approach
  • 0SG04E0 — Fusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG04EJ — Fusion of Lumbar Vertebral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG10E0 — Fusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Open Approach
  • 0SG10EJ — Fusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Open Approach
  • 0SG13E0 — Fusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Approach
  • 0SG13EJ — Fusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Approach
  • 0SG14E0 — Fusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG14EJ — Fusion of 2 or more Lumbar Vertebral Joints with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG30E0 — Fusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Open Approach
  • 0SG30EJ — Fusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Open Approach
  • 0SG33E0 — Fusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Approach
  • 0SG33EJ — Fusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Approach
  • 0SG34E0 — Fusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Anterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0SG34EJ — Fusion of Lumbosacral Joint with Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed, Posterior Approach, Anterior Column, Percutaneous Endoscopic Approach
  • 0W99003 — Drainage of Right Pleural Cavity with Drainage Device, Active Mechanical Clearance, Open Approach
  • 0W99303 — Drainage of Right Pleural Cavity with Drainage Device, Active Mechanical Clearance, Percutaneous Approach
  • 0W99403 — Drainage of Right Pleural Cavity with Drainage Device, Active Mechanical Clearance, Percutaneous Endoscopic Approach
  • 0W9B003 — Drainage of Left Pleural Cavity with Drainage Device, Active Mechanical Clearance, Open Approach
  • 0W9B303 — Drainage of Left Pleural Cavity with Drainage Device, Active Mechanical Clearance, Percutaneous Approach
  • 0W9B403 — Drainage of Left Pleural Cavity with Drainage Device, Active Mechanical Clearance, Percutaneous Endoscopic Approach
  • 0W9C003 — Drainage of Mediastinum with Drainage Device, Active Mechanical Clearance, Open Approach
  • 0W9C303 — Drainage of Mediastinum with Drainage Device, Active Mechanical Clearance, Percutaneous Approach
  • 0W9C403 — Drainage of Mediastinum with Drainage Device, Active Mechanical Clearance, Percutaneous Endoscopic Approach
  • 30233S5 — Transfusion of High-Dose Immune Globulin into Peripheral Vein, Percutaneous Approach
  • 30243S5 — Transfusion of High-Dose Immune Globulin into Central Vein, Percutaneous Approach
  • 3E00XGF — Introduction of Other Enzymatic/Chemical Agent into Skin and Mucous Membranes, External Approach
  • 3E01XGF — Introduction of Other Enzymatic/Chemical Agent into Subcutaneous Tissue, External Approach
  • 5A0527D — Assistance with Circulatory Decompression using Impeller Pump, Continuous
  • 5A1D701 — Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day, Selective Cytopheresis
  • 5A1D801 — Performance of Urinary Filtration, Prolonged Intermittent, 6-18 hours Per Day, Selective Cytopheresis
  • 5A1D901 — Performance of Urinary Filtration, Continuous, Greater than 18 hours Per Day, Selective Cytopheresis
  • B85A2ZZ — Other Imaging of Right Choroid using Fluorescing Agent
  • B85B2ZZ — Other Imaging of Left Choroid using Fluorescing Agent
  • B85G2ZZ — Other Imaging of Right Retinal Vessel using Fluorescing Agent
  • B85H2ZZ — Other Imaging of Left Retinal Vessel using Fluorescing Agent
  • X0HQ05C — Insertion of Leadless Neurostimulator Generator into Vagus Nerve, Open Approach, New Technology Group 12
  • X27P3NC — Dilation of Right Anterior Tibial Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X27Q3NC — Dilation of Left Anterior Tibial Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X27R3NC — Dilation of Right Posterior Tibial Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X27S3NC — Dilation of Left Posterior Tibial Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X27T3NC — Dilation of Right Peroneal Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X27U3NC — Dilation of Left Peroneal Artery with Intraluminal Device(s), Small-diameter, Percutaneous Approach, New Technology Group 12
  • X28M3DC — Division of Ventricular Septum using Transcatheter Septal Scoring Technique, Percutaneous Approach, New Technology Group 12
  • X2H43MC — Insertion of Temporary Intraluminal Device, Venous Angle Decompression using Impeller Pump into Left Innominate Vein, Percutaneous Approach, New Technology Group 12
  • X2RF3LC — Replacement of Aortic Valve using Zooplastic Tissue, with Integrated Native Leaflet Clipping Locators, Percutaneous Approach, New Technology Group 12
  • X2RG3FC — Replacement of Mitral Valve with Balloon-expandable Bioprosthetic Valve with Dock, Percutaneous Approach, New Technology Group 12
  • X2RH0GC — Replacement of Pulmonary Valve using Size-Adjustable Synthetic Substitute, Open Approach, New Technology Group 12
  • X2VJ3HC — Restriction of Thoracic Aorta, Ascending and Arch using Branched Intraluminal Device, Integrated System with Innominate Branch, Percutaneous Approach, New Technology Group 12
  • X2VW3JC — Restriction of Thoracic Aorta, Descending using Branched Intraluminal Device, Integrated System Extension, Percutaneous Approach, New Technology Group 12
  • X2VX0KC — Restriction of Thoracic Aorta, Arch using Branched Intraluminal Device, with Conical Collar, Open Approach, New Technology Group 12
  • XEZ5XKC — Computer-Aided Triage and Notification for Imaging Abnormalities in Computed Tomography of Chest, Abdomen and Pelvis, New Technology Group 12
  • XEZD3QC — Pericardial Cavity Access using Blunt-tip Concealed Needle with Mechanical Gripping Mechanism, Percutaneous Approach, New Technology Group 12
  • XEZJ3NC — Coronary Artery Access using Image-Guided Crossing and Re-entry System, Percutaneous Approach, New Technology Group 12
  • XEZU3HC — Computer-Aided Guidance for Intraprocedural Navigation using Ultrasound Imaging with Continuous Needle Tracking in Spinal Canal, Percutaneous Approach, New Technology Group 12
  • XEZZXJC — High Dimensional Mixture-of-Experts Computer-aided Assessment of Inflammatory Response and Organ Function, for Notification and Triage, New Technology Group 12
  • XEZZXLC — Computer-Aided Detection and Notification for Imaging Abnormalities in Echocardiography, New Technology Group 12
  • XEZZXMC — Computer-Aided Detection and Notification for Abnormalities in Electrocardiogram, New Technology Group 12
  • XEZZXPC — Cardiac Conduction Mechanism, Computer-aided Guidance for Three Dimensional Intraprocedural Navigation using Fluoroscopic Imaging, New Technology Group 12
  • XEZZXRC — Computer-Aided Detection and Notification of Cardiac Abnormalities using Vital Signs, New Technology Group 12
  • XEZZXSC — Cardiac Conduction Mechanism, Computer-aided Intraprocedural Visualization for Guidance, New Technology Group 12
  • XFJB3CC — Inspection of Hepatobiliary Duct using Single-use Choledochoscope, Percutaneous Approach, New Technology Group 12
  • XFJB4CC — Inspection of Hepatobiliary Duct using Single-use Choledochoscope, Percutaneous Endoscopic Approach, New Technology Group 12
  • XFJB8BC — Inspection of Hepatobiliary Duct using Single-use Cholangioscope, Via Natural or Artificial Opening Endoscopic Approach, New Technology Group 12
  • XFJD3CC — Inspection of Pancreatic Duct using Single-use Choledochoscope, Percutaneous Approach, New Technology Group 12
  • XFJD4CC — Inspection of Pancreatic Duct using Single-use Choledochoscope, Percutaneous Endoscopic Approach, New Technology Group 12
  • XFJD8BC — Inspection of Pancreatic Duct using Single-use Cholangioscope, Via Natural or Artificial Opening Endoscopic Approach, New Technology Group 12
  • XHH80JC — Insertion of Contractility Modulation Device with Defibrillator Generator into Chest Subcutaneous Tissue and Fascia, Open Approach, New Technology Group 12
  • XRH10NC — Insertion of Carbon/PEEK Spinal Stabilization Device into Cervical Vertebral Joint, Open Approach, New Technology Group 12
  • XRH13NC — Insertion of Carbon/PEEK Spinal Stabilization Device into Cervical Vertebral Joint, Percutaneous Approach, New Technology Group 12
  • XRH14NC — Insertion of Carbon/PEEK Spinal Stabilization Device into Cervical Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 12
  • XRH20NC — Insertion of Carbon/PEEK Spinal Stabilization Device into 2 or more Cervical Vertebral Joints, Open Approach, New Technology Group 12
  • XRH23NC — Insertion of Carbon/PEEK Spinal Stabilization Device into 2 or more Cervical Vertebral Joints, Percutaneous Approach, New Technology Group 12
  • XRH24NC — Insertion of Carbon/PEEK Spinal Stabilization Device into 2 or more Cervical Vertebral Joints, Percutaneous Endoscopic Approach, New Technology Group 12
  • XRH40NC — Insertion of Carbon/PEEK Spinal Stabilization Device into Cervicothoracic Vertebral Joint, Open Approach, New Technology Group 12
  • XRH43NC — Insertion of Carbon/PEEK Spinal Stabilization Device into Cervicothoracic Vertebral Joint, Percutaneous Approach, New Technology Group 12
  • XRH44NC — Insertion of Carbon/PEEK Spinal Stabilization Device into Cervicothoracic Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 12
  • XRH60NC — Insertion of Carbon/PEEK Spinal Stabilization Device into Thoracic Vertebral Joint, Open Approach, New Technology Group 12
  • XRH63NC — Insertion of Carbon/PEEK Spinal Stabilization Device into Thoracic Vertebral Joint, Percutaneous Approach, New Technology Group 12
  • XRH64NC — Insertion of Carbon/PEEK Spinal Stabilization Device into Thoracic Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 12
  • XW0134C — Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12
  • XW0336C — Introduction of Landiolol Antiarrhythmic into Peripheral Vein, Percutaneous Approach, New Technology Group 12
  • XW0337C — Introduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12
  • XW0436C — Introduction of Landiolol Antiarrhythmic into Central Vein, Percutaneous Approach, New Technology Group 12
  • XW0Q35C — Introduction of Ifezuntirgene Inilparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 12
  • XW0U0CC — Introduction of Recombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold into Joints, Open Approach, New Technology Group 12
  • XW0V0BC — Introduction of Vancomycin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 12
  • XXE2XHC — Measurement of Cardiac Conduction Mechanism, Computer-aided Mapping for Planning, New Technology Group 12

Removed from the code set (38)

  • X2KB317 — Bypass Right Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
  • X2KC317 — Bypass Left Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
  • XD2G4V7 — Monitoring of Upper GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
  • XD2G8V7 — Monitoring of Upper GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
  • XD2H4V7 — Monitoring of Lower GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
  • XD2H8V7 — Monitoring of Lower GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
  • XRGA0R7 — Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGA3R7 — Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGA4R7 — Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XRGB0R7 — Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGB3R7 — Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGB4R7 — Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XRGC0R7 — Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGC3R7 — Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGC4R7 — Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XRGD0R7 — Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7
  • XRGD3R7 — Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
  • XRGD4R7 — Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
  • XW00X27 — Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7
  • XW01397 — Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW01X27 — Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7
  • XW023X7 — Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
  • XW03367 — Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03377 — Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03387 — Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033B7 — Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW04367 — Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04377 — Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04387 — Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043B7 — Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW0DXR7 — Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7
  • XW0G7R7 — Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7
  • XW0H7R7 — Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7
  • XW133D7 — Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW133F8 — Transfusion of OTL-103 into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW143D7 — Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XXE5XR7 — Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7
  • XXE5XT7 — Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7

Description revised (3)

  • XW0E33B — Introduction of Lunsotogene Parvec-cwha via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11
    Introduction of DB-OTO via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11 → Introduction of Lunsotogene Parvec-cwha via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11
  • XW0V0P7 — Introduction of Gentamicin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7
    Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7 → Introduction of Gentamicin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7
  • XW143F8 — Transfusion of Etuvetidigene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
    Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8 → Transfusion of Etuvetidigene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8

Sources

Official source data

Publisher
Centers for Medicare & Medicaid Services (CMS) and the National Center for Health Statistics (CDC/NCHS)
Release
ICD-10-PCS FY2027
Source file
icd10pcs_codes_2027.txt
File checksum (SHA-256)
e7e08e07050024d362d119bd372c75e3860a568554d0d31eb287b935485ff3c6
Data type
Public domain code descriptions and tabular instructions. No licensed content.
Compared against
icd10pcs_codes_2026_april.txt

MedCoder-derived analysis

Change detection
Every addition, deletion, description revision, billable-status change and tabular-instruction change on this page is computed by diffing the two code-description files above, line by line.
Editorial analysis
The grouping of changes into themes, the successor determinations and the coder-impact notes are written by MedCoder against those files. They are not CMS statements.
Independence
MedCoder is an independent coding reference built on public federal data. It is not affiliated with, endorsed by or certified by CMS, and it is not an official CMS coding tool.

Continue

All releases in the Change Ledger

Cite this page

Reference this page in a research guide, syllabus or article. The release is included because code content changes each year.

MedCoder.ai. "ICD-10-PCS FY2027 code changes." ICD-10-PCS FY2027. https://medcoder.ai/updates/icd10pcs/icd10pcs-fy2027